NCT04935905

Brief Summary

The primary aim of this study is to evaluate the agreement of MIE devices measurement of MIE assisted peak cough flow (PCF) compared with a pneumotachographs during usual MIE care. This will be the first study to do this through range of MIE pressures and include patients who are receiving MIE via a tracheostomy. It will also aim to evaluate the intra-subject repeatability of measures for patients who receive more than one MIE cycle as part of their usual care. It will be the first to measure MIE assisted PCF contemporaneously during intervention using the gold standard pneumotachograph. This will inform treatment effect size and the efficacy of usual practice MIE in augmenting PCF measurements above critical cut off values for effective cough and secretion clearance. Finally the study will also aim to understand how patients perceive the impact of MIE in clearing secretions from their chest by asking them to rate presence of chest secretions pre and post intervention using a visual analogue scale (VAS)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 5, 2020

Completed
10 months until next milestone

Study Start

First participant enrolled

December 4, 2020

Completed
7 months until next milestone

First Posted

Study publicly available on registry

June 23, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2021

Completed
Last Updated

January 26, 2022

Status Verified

January 1, 2022

Enrollment Period

9 months

First QC Date

February 5, 2020

Last Update Submit

January 11, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Agreement of Peak Cough Flow between MIE and pneumotachograph.

    Peak Cough Flow measure the peak flow of expired air during the exsufflation phase of cough or MIE assisted cough

    Data will be collected at the point of recruitment to the study and then be reported within 1 year

Secondary Outcomes (5)

  • Visual Analogue Scale

    Data will be collected at the point of recruitment to the study and then be reported within 1 year

  • Treatment effect size of PCF during usual MIE care

    Data will be collected at the point of recruitment to the study and then be reported within 1 year

  • Exploratory analysis of MIE Pressure and PCF

    Data will be collected at the point of recruitment to the study and then be reported within 1 year

  • Exploratory analysis of MIE inspiratory Volume and PCF

    Data will be collected at the point of recruitment to the study and then be reported within 1 year

  • Intra-subject variance of repeated PCF measures

    Data will be collected at the point of recruitment to the study and then be reported within 1 year

Interventions

This device augments a cough by applying a positive pressure via the upper airway or tracheostomy to increase lung volume to maximal inspiratory capacity, followed by a rapid and quick change to negative pressure to increase expiratory flow and simulate normal cough mechanism

Eligibility Criteria

Age18 Years+
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with neuromuscular related respiratory failure and receiving MIE as part of their usual care

You may qualify if:

  • Patients with neuromuscular disease-related respiratory failure and are receiving MIE as part of their usual care
  • Patients who are clinical stable and documented as such by the supervising clinician
  • Patients who are cognitively intact and have the capacity able to provide informed consent

You may not qualify if:

  • Pregnancy
  • Aged \<18
  • Significant physical or psychiatric co-morbidity that would prevent compliance with trial protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guy's and St. Thomas NHS Foundation Trust

London, SE1 7EH, United Kingdom

Location

MeSH Terms

Conditions

Neuromuscular Diseases

Condition Hierarchy (Ancestors)

Nervous System Diseases

Study Officials

  • Leyla Osman

    Guy's and St Thomas' NHS Foundation Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2020

First Posted

June 23, 2021

Study Start

December 4, 2020

Primary Completion

September 1, 2021

Study Completion

September 1, 2021

Last Updated

January 26, 2022

Record last verified: 2022-01

Locations